Nabilone for Cannabis Dependence: A Pilot Study - Full Text View

Purpose

Cannabis use disorders are an important public health problem in the United States, but there are no effective medications available to treat these disorders. The investigators intend to test a medication with interesting properties, nabilone, as a treatment for cannabis dependence and to study the relationship of this treatment with the brain using functional MRI brain scans. Nabilone and marijuana have similar effects upon behaviors and the human body, suggesting that nabilone may decrease cannabis withdrawal symptoms while allowing treatment-seeking patients to benefit from behavioral treatments when they are trying to stop using cannabis. The investigators propose to assess the relationship of nabilone, when added to behavioral treatment, on cannabis use patterns in cannabis-dependent patients. The investigators also aim to determine the effects of nabilone on performance on neuropsychological tests and to assess the correlation of neuropsychological performance to brain changes using functional MRI brain scans. The investigators hypothesize that patients receiving nabilone will reduce their use of cannabis more than patients receiving placebo during this 10-week treatment trial.

Condition	Intervention	Phase
Cannabis Dependence Marijuana Dependence	Drug: Nabilone Drug: Placebo	Phase 2 Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Nabilone for Cannabis Dependence: A Pilot Study

Resource links provided by NLM:

MedlinePlus related topics: Marijuana

Drug Information available for: Nabilone

U.S. FDA Resources

Further study details as provided by Kevin P. Hill, MD, MHS, Mclean Hospital:

Primary Outcome Measures:

change from baseline in cannabis use at 10 weeks [ Time Frame: baseline and 10 weeks ]
self-report and quantitative cannabis urine screens

Secondary Outcome Measures:

change from baseline neuropsychological performance at 4 weeks [ Time Frame: baseline and 4 weeks ]
performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner
change from baseline cannabis use at 14 weeks [ Time Frame: baseline and 14 weeks ]
self-report and quantitative urine screens
change from baseline in neuropsychological performance at 10 weeks [ Time Frame: baseline and 10 weeks ]
performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner


Estimated Enrollment:	60
Study Start Date:	June 2010
Estimated Study Completion Date:	April 2017
Estimated Primary Completion Date:	April 2017 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Nabilone nabilone titrated to 2 mg daily	Drug: Nabilone nabilone titrated to 1 mg by mouth twice daily Other Name: Nabilone (Cesamet), CSA Drug Code 7379, Schedule II, NDC 0037-1221-50
Placebo Comparator: Placebo Placebo	Drug: Placebo one placebo capsule by mouth twice daily

Detailed Description:

Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders. The investigators intend to test a novel agonist pharmacotherapy, nabilone, for cannabis dependence and to study the relationship of this treatment with the brain using BOLD fMRI measures. The behavioral and physiological effects of nabilone and Δ9-THC overlap, suggesting that nabilone may ameliorate cannabis withdrawal symptoms while allowing treatment-seeking outpatients to benefit from medical management (MM) sessions when they are trying to stop using cannabis. The investigators propose to assess the relationship of nabilone, when added to MM, on cannabis use patterns in cannabis-dependent patients. The investigators also aim to determine the effects of nabilone on performance on neuropsychological tests and to assess the correlation of neuropsychological performance to brain changes using BOLD fMRI measures.

In this pilot study, subjects will receive either nabilone or placebo in addition to medical management (MM) over a 10-week treatment period. Subjects' responses to neuropsychological testing carried out while the subject is receiving fMRI scans at 3 time points: at baseline, 4 weeks, and 10 weeks. Following treatment completion, subjects will have a follow-up visit at 14 weeks. This pilot study will evaluate the feasibility of nabilone treatment for cannabis dependence and will establish effect sizes for a larger trial in which subjects will receive high-dose nabilone, low-dose nabilone, or placebo in addition to MM.

Eligibility


Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age range 18-45 years
DSM-IV diagnosis of cannabis dependence, based on the Structured Clinical Interview for DSM-IV (SCID)
express a desire to quit cannabis use within the next 30 days
have used cannabis on more than4 days within the past 30 days
for women of childbearing age, a negative pregnancy test at screening with agreement to use adequate contraception to prevent pregnancy and monthly pregnancy tests
consent for us to communicate with their prescribing clinician
furnish the names of 2 locators, who would assist study staff in locating them during the study period
live close enough to McLean Hospital to attend study visits
plan to stay in the Boston area for the next 3 months
are willing and able to sign informed consent.

Exclusion Criteria:

current diagnosis of other drug or alcohol dependence (excluding nicotine)
recent (within 3 months) significant cardiac disease
current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder
current medical condition (including significant laboratory abnormalities, such as liver function tests >5 times the upper limit of normal range) that could prevent regular study attendance
mental retardation or organic mental disorder
acutely dangerous or suicidal behavior
currently in a residential treatment setting in which substance use is monitored and restricted, since the restricted access to drugs could represent an important confounding variable
pregnant, nursing, or, if a woman of childbearing potential, not using a form of birth control judged by the investigator to be effective
concomitant daily treatment with opioid analgesics, sedative hypnotics, or other known CNS depressants
known hypersensitivity to cannabinoids or sesame oil
disease of the gastrointestinal system, liver, or kidneys that may impede metabolism or excretion of nabilone
inability to read or write in English. The potential hazards of a Schedule II medication like nabilone underscore the importance of English proficiency in this medication trial.
unwilling or unable to participate in MRI scanning (e.g., those having pacemakers, bone plates, screws, etc.; claustrophobia)
a history of seizures, head trauma or other history of CNS insult that could predispose the subject to seizures .

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01347762

Contacts


Contact: Matthew Palastro, BS	617 855 3498	MPALASTRO@PARTNERS.ORG

Locations


United States, Massachusetts
McLean Hospital	Recruiting
Belmont, Massachusetts, United States, 02478
Contact: Matthew Palastro, BS 617-855-3498 MPALASTRO@PARTNERS.ORG
Principal Investigator: Kevin P Hill, MD, MHS

Sponsors and Collaborators

Mclean Hospital

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	Kevin P Hill, MD, MHS	Mclean Hospital

More Information


Responsible Party:	Kevin P. Hill, MD, MHS, Psychiatrist-In-Charge, Mclean Hospital
ClinicalTrials.gov Identifier:	NCT01347762 History of Changes
Other Study ID Numbers:	2010-P-000096 1K99DA029115-01 ( US NIH Grant/Contract Award Number )
Study First Received:	April 26, 2011
Last Updated:	September 12, 2016

Keywords provided by Kevin P. Hill, MD, MHS, Mclean Hospital:


cannabis dependence marijuana dependence cannabis use disorders cannabis withdrawal nabilone

Additional relevant MeSH terms:


Marijuana Abuse Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Nabilone Dronabinol Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Anti-Anxiety Agents Tranquilizing Agents	Central Nervous System Depressants Psychotropic Drugs Hallucinogens Analgesics, Non-Narcotic Analgesics Sensory System Agents Cannabinoid Receptor Agonists Cannabinoid Receptor Modulators Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Hormones Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on May 25, 2017

Nabilone for Cannabis Dependence: A Pilot Study (NAB CAN)